The Impact of Cetuximab on Apoptotic and Autophagic Gene Expression in Metastatic Colorectal Cancer Cells



Apoptosis, Autophagy, Cetuximab, Colorectal cancer, Cytotoxicity


Colorectal cancer (CRC) is one of the most frequent cancers, and chemotherapy plays an important role in its treatment. The primary goal of this research was to investigate the apoptotic, autophagic, and cytotoxic effects of cetuximab (CTX), a monoclonal antibody used to treat colorectal cancer. Colorectal cancer cell lines were treated with different doses of cetuximab to create ten test groups, which were then incubated for 24 and 48 hours. The cytotoxicity was determined using the MTT test. Histochemically, the TUNEL assay was employed to identify apoptosis. Real-time PCR was used to determine the expression levels of p21, p27, p57, KRAS, LC3A, BECN1, EGF, and ATG4A genes. The effective dose of cetuximab was determined by the MTT cytotoxicity study to be 10 g/mL. KRAS and EGF gene expression decreased at the same time, but p21, p27, p57, LC3A, BECN1, and ATG4A gene expression increased. With increasing doses of cetuximab, an increase in apoptosis was identified using TUNEL labeling. We may conclude that CTX induces apoptosis and autophagy in HT-29 KRK cells through raising the expression of p21, p27, and p57 genes, as well as ATG4A, LC3A, and BECN1 genes. Furthermore, it is possible to say that reducing EGF and KRAS gene expression inhibits cancer cell growth.


Adjei, A. A. (2001). Blocking oncogenic Ras signaling for cancer therapy. Journal of the National Cancer Institute, 93(14), 1062-1074.

Bruns, C. J., Harbison, M. T., Davis, D. W., Portera, C. A., Tsan, R., McConkey, D. J., Abbruzzese, J. L., Hicklin, D. J., & Radinsky, R. (2000). Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by antiangiogenic mechanisms. Clinical Cancer Research, 6(5), 1936-1948.

Chen, Z., Gao, S. H., Wang, D. Y., Song, D. F., & Feng, Y. (2016). Colorectal cancer cells are resistant to anti-EGFR monoclonal antibody through adapted autophagy. American Journal of Translational Research, 8(2), 1190-1196.

Cordoncardo, C. (1995). Mutation of cell-cycle regulators biological and clinical implications for human neoplasia. American Journal of Pathology, 147(3), 545-560.

de Farias, C. B., Heinen, T. E., dos Santos, R. P., Abujamra, A. L., Schwartsmann, G., & Roesler, R. (2012). BDNF/TrkB signaling protects HT-29 human colon cancer cells from EGFR inhibition. Biochemical and Biophysical Research Communications, 425(2), 328-332.

Deschenes, C., Vezina, A., Beaulieu, J. F., & Rivard, N. (2001). Role of p27(Kip1) in human intestinal cell differentiation. Gastroenterology, 120(2), 423-438.

Feng, Y., Gao, S. H., Gao, Y. J., Wang, X. F., & Chen, Z. (2016). Anti-EGFR antibody sensitizes colorectal cancer stem-like cells to Fluorouracil-induced apoptosis by affecting autophagy. Oncotarget, 7(49), 81402-81409.

Huang, S. M., Bock, J. M., & Harari, P. M. (1999). Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck. Cancer Research, 59(8), 1935-1940.

Huether, A., Hopfner, M., Baradari, V., Schuppan, D., & Scherubl, H. (2005). EGFR blockade by cetuximab alone or as combination therapy for growth control of hepatocellular cancer. Biochemical Pharmacology, 70(11), 1568-1578.

Inoue, K., Slaton, J. W., Perrotte, P., Davis, D. W., Bruns, C. J., Hicklin, D. J., McConkey, D. J., Sweeney, P., & Dinney, C. P. N. (2000). Paclitaxel enhances the effects of the anti-epidermal growth factor receptor monoclonal antibody ImClone C225 in mice with metastatic human bladder transitional cell carcinoma. Clinical Cancer Research, 6(12), 4874-4884.

Jhawer, M., Goel, S., Wilson, A. J., Montagna, C., Ling, Y. H., Byun, D. S., Nasser, S., Arango, D., Shin, J., Klampfer, L., Augenlicht, L. H., Perez-Soler, R., & Mariadason, J. M. (2008). PIK3CA mutation/PTEN expression status predicts response of colon cancer cells to the epidermal growth factor receptor inhibitor cetuximab. Cancer Research, 68(6), 1953-1961.

Levine, B., & Kroemer, G. (2008). Autophagy in the pathogenesis of disease. Cell, 132(1), 27-42.

Li, G. J., Liu, Z. S., Sturgis, E. M., Shi, Q. L., Chamberlain, R. M., Spitz, M. R., & Wei, Q. Y. (2005). Genetic polymorphisms of p21 are associated with risk of squamous cell carcinoma of the head and neck. Carcinogenesis, 26(9), 1596-1602.

Li, X. Q., Lu, Y., Pan, T. H., & Fan, Z. (2010). Roles of autophagy in cetuximab-mediated cancer therapy against EGFR. Autophagy, 6(8), 1066-1077.

Lievre, A., Bachet, J. B., Le Corre, D., Boige, V., Landi, B., Emile, J. F., Cote, J. F., Tomasic, G., Penna, C., Ducreux, M., Rougier, P., Penault-Llorca, F., & Laurent-Puig, P. (2006). KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Research, 66(8), 3992-3995.

Lim, D. Y., Jeong, Y., Tyner, A. L., & Park, J. H. Y. (2007). Induction of cell cycle arrest and apoptosis in HT-29 human colon cancer cells by the dietary compound luteolin. American Journal of Physiology-Gastrointestinal and Liver Physiology, 292(1), G66-G75.

Liu, B., Fang, M., Schmidt, M., Lu, Y., Mendelsohn, J., & Fan, Z. (2000). Induction of apoptosis and activation of the caspase cascade by anti-EGF receptor monoclonal antibodies in DiFi human colon cancer cells do not involve the c-jun N-terminal kinase activity. British Journal of Cancer, 82(12), 1991-1999.

Luporsi-Gely, E., Pestalozzi, B., Jost, L., & Force, E. G. T. (2001). ESMO Minimum Clinical Recommendations for diagnosis, adjuvant treatment and follow-up of primary breast cancer. Annals of Oncology, 12(8), 1047-1048.

Maclachlan, T. K., Sang, N. L., & Giordano, A. (1995). Cyclins, cyclin-dependent kinases and cdk inhibitors - implications in cell-cycle control and cancer. Critical Reviews in Eukaryotic Gene Expression, 5(2), 127-156.

Mandal, M., Adam, L., Mendelsohn, J., & Kumar, R. (1998). Nuclear targeting of Bax during apoptosis in human colorectal cancer cells. Oncogene, 17(8), 999-1007.

McKay, J. A., Murray, L. J., Curran, S., Ross, V. G., Clark, C., Murray, G. I., Cassidy, J., & McLeod, H. L. (2002). Evaluation of the epidermal growth factor receptor (EGFR) in colorectal tumours and lymph node metastases. European Journal of Cancer, 38(17), 2258-2264, Article Pii s0959-8049(02)00234-4.

Mendelsohn, J. (2000). Jeremiah Metzger Lecture. Targeted cancer therapy. Transactions of the American Clinical and Climatological Association, 111, 95-111.

Mendelsohn, J., & Baselga, J. (2003). Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. Journal of Clinical Oncology, 21(14), 2787-2799.

Mizushima, N., Levine, B., Cuervo, A. M., & Klionsky, D. J. (2008). Autophagy fights disease through cellular self-digestion. Nature, 451(7182), 1069-1075.

Polat, S. (2015). Investigation the Effects of Melatonin and Cisplatin Treatment on Autophagy andApoptosis in Colorectal Cancer Cells. [Master Thesis], Ataturk University.

Polyak, K., Lee, M. H., Erdjumentbromage, H., Koff, A., Roberts, J. M., Tempst, P., & Massague, J. (1994). Cloning of p27(kip1), a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell, 78(1), 59-66.

Rouschop, K. M. A., & Wouters, B. G. (2009). Regulation of Autophagy Through Multiple Independent Hypoxic Signaling Pathways. Current Molecular Medicine, 9(4), 417-424.

Shao, Z. M., Wu, J. O., Shen, Z. Z., & Barsky, S. H. (1998). Genistein inhibits both constitutive and EGF-stimulated invasion in ER-negative human breast carcinoma cell lines. Anticancer Research, 18(3A), 1435-1439.

Sherr, C. J. (1996). Cancer cell cycles Science, 274(5293), 1672-1677.

Shintani, T., & Klionsky, D. J. (2004). Autophagy in health and disease: A double-edged sword. Science, 306(5698), 990-995.

Solmi, R., Lauriola, M., Francesconi, M., Martini, D., Voltattorni, M., Ceccarelli, C., Ugolini, G., Rosati, G., Zanotti, S., Montroni, I., Mattei, G., Taffurelli, M., Santini, D., Pezzetti, F., Ruggeri, A., Castellani, G., Guidotti, L., Coppola, D., & Strippoli, P. (2008). Displayed correlation between gene expression profiles and submicroscopic alterations in response to cetuximab, gefitinib and EGF in human colon cancer cell lines. Bmc Cancer, 8, Article 227.

Tabernero, J., Cervantes, A., Rivera, F., Martinelli, E., Rojo, F., von Heydebreck, A., Macarulla, T., Rodriguez‐Braun, E., Vega‐Villegas, M. E., Senger, S., Ramos, F. J., Rosello, S., Celik, I., Stroh, C., Baselga, J., & Ciardiello, F. (2010). Pharmacogenomic and Pharmacoproteomic Studies of Cetuximab in Metastatic Colorectal Cancer: Biomarker Analysis of a Phase I Dose-Escalation Study. Journal of Clinical Oncology, 28(7), 1181-1189.

Torre, L. A., Siegel, R. L., Ward, E. M., & Jemal, A. (2016). Global Cancer Incidence and Mortality Rates and Trends-An Update. Cancer Epidemiology Biomarkers & Prevention, 25(1), 16-27.

Tortora, G., Caputo, R., Pomatico, G., Pepe, S., Bianco, A. R., Agrawal, S., Mendelsohn, J., & Ciardiello, F. (1999). Cooperative inhibitory effect of novel mixed backbone oligonucleotide targeting protein kinase A in combination with docetaxel and anti-epidermal growth factor-receptor antibody on human breast cancer cell growth. Clinical Cancer Research, 5(4), 875-881.

Tsihlias, J., Kapusta, L., & Slingerland, J. (1999). The prognostic significance of altered cyclin-dependent kinase inhibitors in human cancer. Annual Review of Medicine, 50, 401-423.

Weinberg, R. A. (1995). The retinoblastoma protein and cell-cycle control. Cell, 81(3), 323-330.

Wu, X. P., Fan, Z., Masui, H., Rosen, N., & Mendelsohn, J. (1995). Apoptosis induced by an antiepidermal growth-factor receptor monoclonal-antibody in a human colorectal-carcinoma cell cine and its delay by insulin. Journal of Clinical Investigation, 95(4), 1897-1905.

Xiong, Y., Hannon, G. J., Zhang, H., Casso, D., Kobayashi, R., & Beach, D. (1993). P21 is a universal inhibitor of cyclin kinases. Nature, 366(6456), 701-704.

Yang, Z. F., & Klionsky, D. J. (2010). Eaten alive: a history of macroautophagy. Nature Cell Biology, 12(9), 814-822.

Zieske, J. D. (2000). Expression of cyclin-dependent kinase inhibitors during corneal wound repair. Progress in Retinal and Eye Research, 19(3), 257-270.




How to Cite

Özgeriş, F. B., Keleş, M. S., Balkan , E., Kara, A., & Kurt , N. (2021). The Impact of Cetuximab on Apoptotic and Autophagic Gene Expression in Metastatic Colorectal Cancer Cells. Natural Products and Biotechnology, 1(2), 106–117. Retrieved from



Research Article

Most read articles by the same author(s)